Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2022

View Archived Issues

Targeting secretogranin III induces antiangiogenic effect during choroidal neovascularization

Dual Kv7 channel/TPSO receptor activator GRT-X shows promise in a refractory seizure model

Betta Pharmaceuticals discovers CD73 inhibitors

New MET/MERTK/TRYO3/AXL inhibitors identified at Aucentra Therapeutics

New IL-17RA antagonists presented by Hitgen

Shanghai Institute of Materia Medica patents glucose-lowering agents

Chengdu Fanxi Biopharma identifies PPAR-alpha and/or PPAR-delta agonists

New antipsychotic shows partial agonist activity at DRD2/3 and 5-HT1AR with little 5-HT2AR binding

STI-1558 strongly inhibits Omicron variant in cell-based assays

ATH-434 demonstrates efficacy in preclinical multiple system atrophy

Design of a next-generation cell-based therapy against diabetes

Improved retinal transplants ready for clinical trials

IDE-161 enters IND-enabling studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 4, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...